modest commerci uptak differenti valu creation
long-term celgen gilead recent car-t acquisit juno kite highlight
import cell therapi view futur driver
hematology-oncolog space launch could prove commerci challeng
onset sever year post launch import drive top-lin
growth gilead diversifi concentr risk celgen end spoke
hematolog kol better understand nuanc commerci
complex well potenti implic competit
landscap follow data overal remain posit car-t
space anticip improv uptak reimburs oper issu
evolv next year consist kol feedback believ initi
car-t turnaround vein-to-vein time time could primari factor initi
favor yescarta support overweight thesi gilead howev
potenti improv efficaci safetywhich could result market
convert outpati modelar like becom key differenti least
nhl think need born comfort
celgen given updat integr car-t model addit
host confer call today friday februari lead
lymphoma kol also review car-t space slide us
addit heme-onc feedback car-t therapi kol indic yescarta would
well posit earli potenti advantag long-term
commun excit potenti car-t nhl initi
uptak car-t like remain slow due commerci oper issu
requir year resolv current turn-around time critic
differenti give yescarta key advantag near-term propos day
vein-to-vein time long-term potenti improv safeti profil
least nhl may provid strong advantagealthough data earli
kol uncertain prospect move earlier nhl/all believ
combin approach refractori diseas like next step
implic gilead base current model assumpt estim
addit yescarta sale add pp revenu earn
cagr increment peak yescarta sale add npv
valu reflect inferior margin rel virolog busi
implic celgen estim addit sale
add almost pp revenu earn compound-annual-growth-rate
increment peak sale add npv valu
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
car-t model updat implic
recent approv kymriah yescarta repres signific leap treatment
nhl respect car-t technolog offer addit potenti
liquid well possibl solid tumor view support gilead celgen
recent decis acquir late stage car-t develop kite juno respect
diversifi revenu stream help drive mid- late-stag growth see gilead reinstat
overweight pt celg thought juno acquisit celg
follow-up thought juno acquisit moreov believ
yescarta us approv expect like benefit larg
commerci oper footprint gilead celgen respect
commerci launch kymriah yescarta proven challeng howev
reflect manufactur administr complex novel therapi
addit high cost treatmentnot associ car-t also
necessari hospit care servic requir administrationha lead
reimburs challeng note
gilead announc yescarta net product revenu news report
publish last decemb reveal two month follow us approv oct
patient treat due reimburs issu see link
call gilead report certifi center januari
upon us approv octob toward goal least initi
total center rem certifi kymriah approv aug
fulli oper addit commerci detail provid
given report car-t commerci challeng includ present last
year see updat monday session well
limit insight guidanc provid previou week earn call spoke
number us kol familiar car-t trial perspect well
clinic perspect get better sens current commerci challeng
like impact market growth addit especi given celgen recent acquisit
juno want get better sens current impress outlook
follow present data ashalong potenti
implic kymriah yescarta see smid-cap analyst gena wang coverag
juno abstract show consist durabl efficaci potenti
takeaway impact updat forecast car-t space
treatment specialist strongli excit launch car-t nhl
indic strong likelihood use
initi use car-t like remain low least given
resourc technic requirementsboth within hospit set includ
apheresi support care follow administr well manufactur
like earli differenti turnaround time given need rapid
intervent signal yescarta turnaround time day signific
advantag kymriah day turnaround time could compar
manag state less day although believ least line
kymriah vector select co-stimul domain like impact
treatment select decis least near-term
longer term believ safeti eas administr like
becom signific differenti agre data earli mani kol
indic support pivot data improv safeti profil offer
strong potenti differenti longer-termassum efficaci turn-around
time par kymriah yescarta stress option treat
outpati set current develop would strong sell payer
base input updat forecast kymriah yescarta
like major indic nhl cll mcl reduc initi penetr
rate therapi reflect commerci challeng first year
follow launch nhl assum eventu achiev slightli higher
share market conserv account potenti safeti differenti
likewis assum kymriah captur slightli greater portion pediatr
market assum pariti market given lack data adult cll mcl
barclay car-t market model kymriah yescarta adjust
gilead base current assumpt estim addit yescarta
sale add pp revenu earn cagr see figur moreov
estim increment peak yescarta sale add
npv valu hematolog indic exclud solid tumor margin inferior
profit virolog franchis see figur celgen base current
assumpt estim addit sale add almost pp
revenu earn compound-annual-growth-rate see figur moreov estim
increment peak sale add npv valu
hematolog indic exclud solid tumor revlimid margin meaning
gilead impact yescarta sale
celgen impact sale
gilead increment sale impact share
celgen increment sale impact
treatment commun excit prospect car-t r/rnhl
kol unanim consider excit within treatment
commun car-t therapi may note current avail
treatment significantli reduc relapsed/refractori nhl patient popul
high year ago littl progress made reduc
percentag specialist therefor optimist car-t would provid
signific benefit patient fail current treatment
car-t revenuerevenueearningcurrentassumpt yescartaat yescartarevenu million addit valu per car-t revenuesrevenuesearningscurrentassumpt million addit valu per celg barclay biopharmaceut
think entir commun drink kool-aid one think
question get academ center technolog effect
weve seen clinic trial
rrnhl popul hasnt chang much rituximab cure
patient up-front set around number patient move
rrnhl use ibrutinib rchop better way monitor
patient noth move bar cure patient
left difficult treat that hope car-t
uptak car-t like continu slow due remain
commerci challeng due technic oper complex
well access appropri hospitals/treat center experienc
despit posit outlook excit car-t aggress nhl kol
stress uptak car-t like remain low primarili due continu
commerci issu none also express surpris regard report access
specialist emphas technic requir produc car-t
signific sever potenti develop challeng could slow output
potenti issu involv nearli everi aspect manufactur process includ
poor/limit transduct effici slower expect modifi t-cell expans
issu purifi packag cell given limit number center gilead
report certifi center januari upon us approv
octob initi state goal technic issu kol
caution initi use may continu limit throughout near-term
beyond potenti issu gilead center treatment specialist also highlight
treatment facil addit issu may blunt uptak hospit lab limit
capabl oper expertis apheresi step resourc share among
rest patient may delay treatment chemotherapi modifi t-cell
infus step must also schedul patient vy resourc
beyond treatment kol also point need appropri treatment
center given scope extent potenti safeti issu cytokin releas
syndrom neurotox specialist emphas care center need
experienc person physician support staff capabl familiar
treatment potenti fatal side effect
reason kol indic treatment penetr may requir signific
great therapi dont get wrong con two-fold non-tox
extrem resourc intens mani us believ treatment
start move beyond dedic center your go patient
wait therapi patient dont time
center demand lab apheresi
factor delay product like issu cultur could
anoth signific hurdl make sure appropri support care
deal toxic isnt trivial need find experienc peopl facil
know theyr
despit initi challeng may potenti result lower orr
observ clinic studi kol expect issu resolv
time
reason outlin sever kol opin initi overal efficaci
number car-t may significantli lower post trial due
mix potenti oper administr technic issu includ potenti
challeng rang schedul patient apheresi potenti product delay
could limit treatment access reduc efficaci valu intent-to-treat
basi denomin includ patient start complet treatment
specialist howev remain optimist issu would resolv time
suffici resourc alloc procedur overal number center
increas experi expertis level grow though will
specul much time would take opin situat would requir
order year resolv take longest rural communities/
would anticip analyz number intent-to-treat orr would
go enrol patient never get therapi there select bia
that problem go see technolog go live
low bump would hope goe away there lot room
improv regard avail resourc overal bandwidth
oh definit resolv next coupl year go come
wave itll take longest patient rural commun away
treatment center go least access theyll wait awhil
car-t turnaround time consid current key differenti
yescarta kymriah efficaci safeti profil consid
similar upsid co-stimulatori domain vector composit unclear
specialist spoke emphas current key differenti
differ car-t program turnaround time cite real world practic differ see
skeptic entir process would take less week
mani suggest time could longer depend geograph locat
patient nearli kol indic unlik either compani would meet
project target turnaround time day yescarta day kymriah
respect given patholog state patient requir car-t therapi kol
stress time signific factorand even littl time week could
substanti impact outcom
beyond turnaround time kol indic littl differenti
two current approv program kymriah yescartaat least current base
trial data specialist report clinic trial efficaci appear line
safeti issu look similar sever opin might requir much greater studi
includ real world-us determin substant differ efficaci
safeti two co-stimulatori domain current use theoret posit
neg potenti issu none kol concern
type vector indic concern regard rcr insert
advantag one quickest turnov kymriah realli
turn around day that import patient stage need
car-t treatment wait long
dont know attribut favor point earli
specul cant assum prolifer see betterit could
wind ad select pressur antigen escap could
ultim toxic
dont realli see differ yescarta kymriah
similar efficaci similar toxicitiesi dont think real word data reveal
longer term manufactur treatment technic issu
resolv kol anticip safeti eas administr becom
key differentiatorsespeci turnaround-tim began declin and/or
specialist gener uncertain long would take resolv car-
commerci issu agreement process becam
routin consist turnaround time would becom less signific differenti
factor given mani felt efficaci level differ therapi
compar mani suggest differ safetyeven minorwould becom
signific sourc differenti especi given poor health patient need
treatment howev mani argu clinic data kymriah
yescarta nearli ident unwil indic advantag
although express optim regard potenti celgene/juno see
specialist stress data earli kol indic
improv safeti profil could signific
differenti mid- long-term
specialist gener divid regard celgene/juno though
unanim data earli convinc littl differ
efficaci safeti observ data present last
novemb vs yescarta kymriah juliet
contrast kol significantli posit regard potenti
differenti safeti aspect attribut incorpor
defin cell composit engin cell
separ follow mix togeth defin ratio specialist note
toxic levelsboth rate neurotoxicitiesdid increas
two dose level clear dose-depend increas efficaci
one kol note howev seem clear improv term
compar yescarta kymriah differ rate neurotox
kol disagre extent differ safeti
yescarta kymriah major indic real could becom signific
differentiatorespeci access equal foot turnaround
time similar celgene/juno indic take less day celgene/juno
also begun explor potenti outpati administr support
improv safeti signalswhich kol agre would provid substanti
advantag especi given resourc current expect support administr
kymriah yescarta
term efficaci dont think there much differ kymriah yescarta
celgene/juno look toxic
report theyr equal toxic
think could signal data earli fact thing didnt
chang increas dose level interest
celgene/juno approach interest whether bear someth els
could well adjust ratio cell meaning there
larg safeti differ could pretti big
kol uncertain potenti move earlier line therapi nhl
later indic like indol nhl specialist posit
potenti combin approach
specialist unanim support use car-t relapsed/
refractori set major circumspect move treatment earlier
treatment paradigm mani felt current regimen suffici especi
factor efficaci eas cost treatmentespeci given total
requir resourc car-t kol indic await
clinic trial data didnt believ differ clinic valu would enough
justifi cost time current late-stag car-t
think studi need done go look care make-up
patient take closer look intent-to-treat popul
cr rate could start go add patient think
your treat worst worst warrant
studi power non-inferior that problem there
slight advantag that problem commun contend
cost resourc necessari car-t vs standard care
go requir least year move earlier set talk
studi least patient least year follow-upbecaus
that know fail therapi
kol also hesit specul potenti move later
indic specif indol nhl contrast mani posit
use car-t combin current avail agentsespeci given
potenti reduc toxic associ former
remain seen yescarta impact indol nhl
biolog reason tumor may less amen kind treatment
slower there indic disabl immun system surveil
may harder get upregul car-t necessari treatment
like definit tip iceberg come car-t
combin happen combin car-t revlimid histon
deacetylas inhibitor field ripe studi think legitim next
wave there plenti rational believ combin approach would
better could potenti address toxic
chimer antigen receptor car-t cell therapi novel cell-bas immunotherapi
cancer part treatment patient t-cellsa specif type white blood
cellar harvest taken special facil center subset t-cell
select reprogram via genet engin select identifi specif cellular
marker antigen associ patient cancer t-cell
reintroduc back patient target destroy cancer cell car-t
cell also prolifer may provid long-last protect reoccurr
current car-t cell therapi demonstr activ certain hematolog
cancer due avail good antigensmark express primarili
tumor cell normal tissu current late stage approv program target
associ b-cell malign includ acut lymphoblast leukemia
non-hodgkin lymphoma nhl includ diffus larg cell lymphoma dlbcl
follicular lymphoma fl chronic lymphocyt leukemia cll anoth antigen
target current late stage program bcma b-cell matur antigen
associ multipl myeloma mm
contrast car-t cell therapi demonstr limit efficaci treatment solid
tumor potenti theori includ lack known ideal tumor antigen
challeng oper within tumor microenviron
current three approved/ late-stag clinic program car-t space focus
yescarta kymriah celgene/juno
major differenti point regard differ program includ
composit contain three distinct element extracellular
domain target antigen spacer transmembran domain
intra-cellular domain respons activ t-cell co-
stimul current either current advanc nhl car-
therapi approv develop target differ
co-stimul domain differ
complet character current evid suggest contribut
improv persist respons greater t-cell expans
manufacturing/turnaround time program vari time requir produc
car-t therapi collect transduc t-cell car-t vector
select expand popul modifi cell perform necessari
qualiti assur packag treatment deliveri administr
gilead indic target turnaround time day vein-to-vein
contrast car-t kymriah turnaround time day approv pediatr
contrast celgene/juno declin specifi precis turnaround time offer
could deliv less day
vector select vector late-stag use base
pathogen virus lentivir vector develop hiv gamma-retrovir vector
develop murin leukemia viru long-term concern car-t therapi
includ potenti issu deriv vector replic compet retroviru rcr
insert mutagenesi due random vector integr
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
author contribut research report research analyst unless otherwis indic
public date top report reflect local time report produc may differ releas date provid
gmt
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis barclay research depart
oper independ absa research depart absa research produc absa bank limit act corpor
invest bank divis part barclay africa group limit affili invest bank barclay bank plc elig
client may receiv research report research depart may reach differ conclus may contain differ
conflict forecast recommend trade idea
price sourc thomson reuter last avail close price relev trade market unless anoth time sourc
barclay bank plc and/or affili lead manag co-lead manag publicli disclos offer secur issuer
 employe non-execut director barclay bank plc and/or affili director issuer
cd barclay bank plc and/or affili market-mak debt secur issu issuer
ce barclay bank plc and/or affili market-mak equiti secur issu issuer
barclay bank plc and/or affili receiv compens invest bank servic issuer past month
 barclay bank plc and/or affili expect receiv intend seek compens invest bank servic issuer
within next month
fa barclay bank plc and/or affili benefici own class equiti secur issuer calcul accord
us regul
fb barclay bank plc and/or affili benefici own long posit class equiti secur issuer
calcul accord eu regul
fc barclay bank plc and/or affili benefici own short posit class equiti secur issuer
calcul accord eu regul
gd one analyst fundament credit coverag team member household financi interest debt
equiti secur issuer
ge one analyst fundament equiti coverag team member household financi interest debt
equiti secur issuer
 issuer benefici own class common equiti secur barclay plc
